Search results for Lucatumumab
Lucatumumab, Abbexa, abx831089
Lucatumumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting CD40, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. HCD122 is a fully human, antagonist antibody that targets the CD40 antigen. HCD122 binds to tumor cells that express CD40 and antagonizes (prevents) CD40 ligand-mediated growth and survival of malignant B cells. Based on preclinical data, HCD122 also induces antibody-dependent cellular cytotoxicity (ADCC), killing CD40 expressing tumor cells by immune effector cells. This dual mechanism of action makes HCD122 a drug candidate with potential for the treatment of B-cell malignancies.
Host
Human
Reactivity
Human
Applications
ELISA, WB
Conjugation
Unconjugated
Lucatumumab Biosimilar - Research Grade, ichor.bio, ICH5129
Detects human CD40
Host
CHO Cells
Reactivity
Human
Applications
Conjugation
Research Grade Lucatumumab (HB782056), abinScience, HB782056
Host
Human
Reactivity
Human
Applications
ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Conjugation
Please provide the required information below so that we can quickly source your products.